Author Archive: Abigail Hirsch

Abigail Hirsch

Abigail is the Director of Events Communications at BIO. Although she has lived in the Washington, DC, area for nearly eight years, she still considers Virginia Beach home, especially with her parents and closest friends still in the area. According to Abigail, there is nothing better than sitting on the beach with a good book and cold drink. In her spare time, she enjoys visiting antique stores, finishing her twin sister Brooke’s sentences and spending time with her two boys, Frank her English bulldog, and JP her soon-to-be husband. Check back often for updates, Abigail’s take on BIO related events, and much more. And please, be kind, this is her first venture in to the blogging world!

Latest Posts

Convention Veterans Putting the “Super” in Super Sessions

Worldview

Featured in the BIO Buzz Center at last year’s Convention, two of our Super Session participants will once again join us to host a dynamic group of C-level industry thought leaders, sharing their perspectives on the current economic environment and major trends that will impact the future of the global industry. Ernst & Young will present insights from their annual report which looks to measure the industry performance through key metrics such as financial results, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Tracks & Attendees Put the “International” in the BIO International Convention

BIO International Convention

As the BIO International Convention celebrates its 20th year, there is no time like the present to reflect on the evolution of the world’s largest biotechnology industry gathering, and what it illustrates in terms of the patterns of global industry achievements. Overall attendance growth over the years – from a 4,000-strong audience in 1998 to an audience topping 16,000 in 2012 – provides a clear indication of how far this industry has come towards developing and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech

Tony Coles

After a stellar year, as evidenced by inclusion in the second annual FierceBiotech “25 Most Influential People in Bipoharma Today,” N. Anthony (Tony) Coles, MD, Chairman & CEO of Onyx Pharmaceuticals sat down with Steve Usdin, Senior Editor of BioCentury for an early morning Fireside Chat at the 15th Annual BIO CEO & Investor Conference. To read more about Onyx’s stellar year and their company milestones, visit here. The biotech retained complete control in the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Word on the Street – Biotech Stocks Only Have Room to Go Up

Stock Exchange Ticker

The Opening Lunch Plenary at this year’s BIO CEO & Investor Conference was a lively discussion between portfolio managers and senior buy-side analysts looking to forecast the year ahead in biotech. BIO’s own, Celia Economides, Director, Investor Relations & Programs, reminded us all where we were 15 years ago at the inception of this event. At the 1999 event, there were 18 presenting companies, zero 1X1 meetings scheduled and 271 attendees.  As of day one, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Renewing the Project BioShield Act: What Has It Bought and Wrought?

Syringe

In the next several months, the U.S. Government will decide whether to continue the funding and authorities associated with Project BioShield, which expanded the U.S. stockpile of medical countermeasures (MCMs) for potential chemical, biological, radiological and nuclear (CBRN) attacks. Congress established Project BioShield in 2004 and provided $5.68B for procurement over 10 years. Two years later, it created the Biomedical Advanced Research and Development Authority (BARDA) to oversee BioShield’s advanced development and procurement efforts. To Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,